Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 238

Sort by

Sort Order Select

Journal Articles

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Chloé Friedrich, Sylvain Barreau

Blood (2020) 136 (1): 148.

https://doi.org/10.1182/blood.2020005728

Published: 2020

Journal Articles

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Elena Monzón Manzano, Raul Justo Sanz, Diana Hernández, Teresa Álvarez Roman, Ihosvany Fernandez-Bello, Mónica Martín, Larissa Valor, María Isabel Rivas Pollmar, Miguel A Canales, MD PhD, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2019) 134 (Supplement_1): 1089.

https://doi.org/10.1182/blood-2019-125772

Published: 2019

Journal Articles

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, Norifumi Sugawara, MD, PhD, Shinri Miyajima, MD, Kazuki Kiyohara, MD, Maki Nishiya, MD PhD, Tadashi Shimoyama, MD PhD, Yuka Takemasa-Fujisawa, MD PhD, Ryosei Sasaki, MD PhD, Wataru Izumita, MD, Yasuhiko Tsukushi, MD, PhD, Akihiro Otsu, MD, PhD, Takahiro Mine, MD, Takeshi Sugawara, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, PhD, Ichiro Hanamura, MD PhD, Shugo Kowata, MD, PhD, Shigeki Ito, MD, PhD

Blood (2019) 134 (Supplement_1): 4865.

https://doi.org/10.1182/blood-2019-131305

Published: 2019

Journal Articles

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

Mohamed Abu Haleeqa, MBBS, Hanan Al Raeesi, MBBS, Fatima Alkaabi, MBBS

Blood (2019) 134 (Supplement_1): 4799.

https://doi.org/10.1182/blood-2019-126479

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Ghassan Al-Shbool, MD, Sameer Desale, MS, Judith Veis, MD, Vera Malkovska, MD, Sanjal Desai, MD

Blood (2019) 134 (Supplement_1): 2912.

https://doi.org/10.1182/blood-2019-129558

Published: 2019

Journal Articles

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Yan Leyfman, BS, Erel Joffe, MDMSc, Esther Drill, PhD, Sridevi Rajeeve, MD, Andrew D. Zelenetz, MD PhD, Maria Lia Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, MD, Ariela Noy, MD, Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Paul A. Hamlin, MD, Matthew J Matasar, MD, Anita Kumar, MD, Gottfried R. von Keudell, MD PhD, Connie Lee Batlevi, MD PhD, Anas Younes, MD, David J. Straus, MD

Blood (2019) 134 (Supplement_1): 2826.

https://doi.org/10.1182/blood-2019-123257

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

Tine Wyseure, PhD, Niels Behrendt, Annette von Drygalski, MD PharmD, Laurent O Mosnier

Blood (2019) 134 (Supplement_1): 158.

https://doi.org/10.1182/blood-2019-128723

Published: 2019

Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Blood (2019) 134 (Supplement_1): 4145.

https://doi.org/10.1182/blood-2019-126163

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Christopher M Melén, MD, Magali Merrien, MSc, Agata Wasik, MSc, PhD, Kristina Sonnevi, MD PhD, Henna-Riikka Junlén, MD, Birger Christersson, MD PhD, Birgitta Sander, MD PhD Prof., Björn E Wahlin, MD PhD

Blood (2019) 134 (Supplement_1): 5487.

https://doi.org/10.1182/blood-2019-126693

Published: 2019

Journal Articles

Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests

Maria Tenorio, PhD, Gemma Moreno Jiménez, MD, Valentín García Gutiérrez, PhD, Ana Jiménez, Maria Jesús Blanchard, MD, Ana Vallés, Sandra López, Pilar Herrera, MD, Javier Lopez Jimenez, MD PhD, Anabelle Chinea, MD

Blood (2019) 134 (Supplement_1): 4983.

https://doi.org/10.1182/blood-2019-131345

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients

Hao Dai, Sivaramakrishna P. Rachakonda, PhD, Olaf Penack, MD, Aleksandar Radujkovic, MD, Carsten Müller-Tidow, MD, Rajiv Kumar, PhD, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 873.

https://doi.org/10.1182/blood-2019-124742

Published: 2019

Journal Articles

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

Sanjal Desai, MD, Stephen Fernandez, Anusha Vakiti, MD, Facundo Stingo, MD, Tripti Adhikari, MD, Emily Paku, Aarthi Shenoy, MD, Vera Malkovska, MD, Dawn Fishbein, MD

Blood (2019) 134 (Supplement_1): 1614.

https://doi.org/10.1182/blood-2019-127520

Published: 2019

Journal Articles

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Blood (2019) 134 (Supplement_1): 3116.

https://doi.org/10.1182/blood-2019-123205

Published: 2019

Journal Articles

Platelet Protein Glycosylation in Immune Thrombocytopenia

Elena Monzón Manzano, Raul Justo Sanz, Stuart M Haslam, BSc PhD, Leow Ke Xuan, Anne Dell, PhD, Teresa Álvarez-Roman, Mónica Martín, María Isabel Rivas Pollmar, Ihosvany Fernandez-Bello, Miguel A. Canales, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2018) 132 (Supplement 1): 2437.

https://doi.org/10.1182/blood-2018-99-114568

Published: 2018

Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2018-99-116225

Published: 2018

Journal Articles

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

Nawal Faiez Alshehry, MD, Musab Ahmed, MD, Shahid Iq bal, MD, Atta Munawar Gill, MD, Mohammad E Dawiama, MD, Ahmed Ali Butt, MD, Belal Albtoosh, BSc, RN, Ibraheem H. Motabi, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Shanker Raja, MD

Blood (2018) 132 (Supplement 1): 5342.

https://doi.org/10.1182/blood-2018-99-116529

Published: 2018

NARROW

A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment

Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Thrombotic Thrombocytopenia Purpura Case Series in Skmc 2016-2017

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Prevalence of Chronic Kidney Disease (CKD) in Lymphoma Survivors

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Prevention of Bleeding-Induced Vascular Abnormalities in the Hemophilic Mouse Joint By Increasing TAFI Levels or Inhibiting uPA Activity

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients

Virologic Clearance of Hepatitis C Is Associated with Improved Outcomes in African American Patients with Lymphoma

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)

Platelet Protein Glycosylation in Immune Thrombocytopenia

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Role of Serial Positron Emission Tomography (PET) Scans in Indolent Lymphomas' Management - Interim Results from an Ongoing Prospective Study at King Fahd Medical City, Riyadh, Saudi Arabia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only